Clinical Efficacy Evaluation of a Continuous Glucose Monitoring-Guided Forecasting Algorithm to Mitigate Postbariatric Hypoglycemia: A Randomized Controlled Trial.
Arlette Journeaux, Selina Zbinden, Francesco Prendin, Luca Cossu, Olivia Streicher, Eva Rolfes, María Carolina Fragozo-Ramos, Camillo Piazza, Dean Vukovic, Philipp Nett, Daniel Giachino, Joerg Zehetner, Giacomo Cappon, David Herzig, Andrea Facchinetti, Lia Bally
{"title":"Clinical Efficacy Evaluation of a Continuous Glucose Monitoring-Guided Forecasting Algorithm to Mitigate Postbariatric Hypoglycemia: A Randomized Controlled Trial.","authors":"Arlette Journeaux, Selina Zbinden, Francesco Prendin, Luca Cossu, Olivia Streicher, Eva Rolfes, María Carolina Fragozo-Ramos, Camillo Piazza, Dean Vukovic, Philipp Nett, Daniel Giachino, Joerg Zehetner, Giacomo Cappon, David Herzig, Andrea Facchinetti, Lia Bally","doi":"10.1177/15209156261432146","DOIUrl":null,"url":null,"abstract":"<p><p>Postbariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass predisposes to health risks and impaired quality of life. Given limited therapeutic options, we evaluated the efficacy of a continuous glucose monitoring (CGM)-guided forecasting algorithm to reduce PBH. In this randomized trial, 59 participants underwent a standardized meal test and were assigned to receive 5 g of glucose either upon the algorithm's predictive alert (intervention, <i>n</i> = 32) or when plasma glucose declined below 3.0 mmol/L (control, <i>n</i> = 27). Hypoglycemia incidence (<3.0 mmol/L) was 31% in the intervention group and 44% in the control group (<i>P</i> = 0.30). Nadir glucose and time spent below 3.9 and 3.0 mmol/L did not differ significantly between groups. Extrapolation based on previously published glucose dose-response data suggests that increasing the preventive glucose dose to 10 g could reduce hypoglycemia incidence to 9%. While a 5 g preventive dose was insufficient, these simulations indicate that CGM-guided hypoglycemia forecasting warrants evaluation as an approach for reducing postprandial hypoglycemia in individuals with PBH.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"1098-1103"},"PeriodicalIF":7.4000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15209156261432146","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Postbariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass predisposes to health risks and impaired quality of life. Given limited therapeutic options, we evaluated the efficacy of a continuous glucose monitoring (CGM)-guided forecasting algorithm to reduce PBH. In this randomized trial, 59 participants underwent a standardized meal test and were assigned to receive 5 g of glucose either upon the algorithm's predictive alert (intervention, n = 32) or when plasma glucose declined below 3.0 mmol/L (control, n = 27). Hypoglycemia incidence (<3.0 mmol/L) was 31% in the intervention group and 44% in the control group (P = 0.30). Nadir glucose and time spent below 3.9 and 3.0 mmol/L did not differ significantly between groups. Extrapolation based on previously published glucose dose-response data suggests that increasing the preventive glucose dose to 10 g could reduce hypoglycemia incidence to 9%. While a 5 g preventive dose was insufficient, these simulations indicate that CGM-guided hypoglycemia forecasting warrants evaluation as an approach for reducing postprandial hypoglycemia in individuals with PBH.
期刊介绍:
Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.